PAVmed News

Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireMay 7 19:39

PAVmed to Hold a Business Update Conference Call and Webcast on May 14, 2024

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 3, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technol

PR NewswireMay 3 20:35

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned ...

PR NewswireMay 2 20:35

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireMay 2 19:49

PAVmed Partners With Cancer Center to Advance Care

TipRanksMay 1 18:23

PAVmed Subsidiary, Veris Health, Signs Memorandum of Understanding With The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Parties to implement a pilot program of the Veris Cancer Care Platform NEW YORK, April 30, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage m

PR NewswireApr 30 19:35

Lucid Diagnostics Partners With the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 29 20:47

Buy Rating Affirmed for PAVmed on Growth and Valuation Prospects Amidst Product Commercialization

TipRanksApr 15 17:16

Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today

Yahoo FinanceApr 11 06:15

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and...

PR NewswireApr 8 20:30

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO

BenzingaMar 29 20:06

Buy Rating Affirmed for PAVmed With Strategic Focus on Lucid Diagnostics and Veris Cancer Care Amid Adjusted Price Target

TipRanksMar 29 19:46

IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers

Seeking AlphaMar 28 22:01

PAVmed Inc. (NASDAQ:PAVM) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 28 21:47

Analysts Offer Insights on Healthcare Companies: PAVmed (PAVM) and Simulations Plus (SLP)

TipRanksMar 28 21:20

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersAvalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. The company's market cap stands at $16.3 million. Xilio Therapeutics (NASDAQ:XLO) stock moved

BenzingaMar 28 20:06

Q4 2023 PAVmed Inc Earnings Call

Yahoo FinanceMar 28 14:00

Earnings Call Summary | PAVmed(PAVM.US) Q4 2023 Earnings Conference

The following is a summary of the PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript:Financial Performance:PAVmed Inc. reported a 33% increase in quarterly revenue from Lucid Diagnosis primarily from

Futu NewsMar 28 03:27 · Conference Call

SMR, GCTS and GSIW Among Mid-day Movers

Seeking AlphaMar 28 01:22

PAVmed Non-GAAP EPS of -$1.33 Beats by $0.47, Revenue of $1.05M Beats by $0.02M

Seeking AlphaMar 27 12:53